Literature DB >> 1711935

Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells.

J E Gervasoni1, R N Taub, M Rosado, S Krishna, V J Stewart, D M Knowles, K Bhalla, D D Ross, M A Baker, J Lutzky.   

Abstract

The glycoproteins on the surface of HL-60/S wild-type, drug-sensitive human leukemia cells and HL-60/AR anthracycline-resistant cells which do not overexpress the P-glycoprotein, were characterized by labeling with [35S]-methionine, NaB[3H4], phosphorus 32, or sodium iodide I 125. HL-60/S and HL-60/AR cell lysates and membrane fractions tagged with [35S]-methionine or phosphorus 32 showed no significant differences in their protein patterns as analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and by autoradiography. HL-60/S cells labeled with NaB[3H4] yielded glycoproteins that were smeared predominantly in the molecular-weight range of 210,000 and 160,000 Da, with pI values ranging between pH 4 and pH 4.4. In contrast, NaB[3H4]-labeled HL-60/AR cells showed 7-8 discrete glycoproteins within a molecular-weight range of 170,000 and 140,000 Da, with pI values also ranging between pH 4 and pH 4.4. In addition, [3H]-glucosamine incorporation into HL-60/S and HL-60/AR cells revealed that the latter showed lower uptake of [3H]-glucosamine than did the former. Following treatment with tunicamycin, [3H]-glucosamine uptake in HL-60/S cells decreased, whereas that in HL-60/AR cells remained unchanged. Surface-membrane radioiodination of HL-60/S and HL-60/AR cells showed two distinct protein electrophoretic patterns, with differences being observed in both the high-(220-95 kDa) and low-molecular-weight ranges (21 kDa). Flow cytometric analysis of HL-60/S and HL-60/AR cells using myeloid and lymphoid antigen-specific antibodies demonstrated no antigenic differences between HL-60/S and HL-60/AR cells. HL-60/S cells incubated in the presence of tunicamycin, an inhibitor of N-linked glycosylation, or the protein kinase C agonist phorbol 12-myristate 13-acetate (PMA) developed a glycoprotein pattern similar to that observed in HL-60/AR cells. In addition, tunicamycin treatment of HL-60/S cells decreased daunorubicin (DNR) retention and altered its intracellular distribution as compared with that in HL-60/AR cells. These data indicate that HL-60/AR cells do not possess either de novo or amplified high-molecular-weight surface-membrane proteins; instead, existing proteins are hypoglycosylated. These results also show that HL-60/AR cells exhibit the multidrug-resistant phenotype in association with altered membrane glycoproteins of both high (220-95 kDa) and low molecular weight (21 kDa), but without overexpression of the P-glycoprotein. Furthermore, in HL-60/S cells, the multidrug-resistant phenotype is partially inducible by inhibition of N-linked glycosylation of cell-surface proteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711935     DOI: 10.1007/bf00689695

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

2.  Decreased retention of actinomycin D as the basis for cross-resistance in anthracycline-resistant sublines of P388 leukemia.

Authors:  M Inaba; R K Johnson
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

3.  Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).

Authors:  M K Danks; J C Yalowich; W T Beck
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

Review 4.  Multidrug resistance.

Authors:  J A Moscow; K H Cowan
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

Review 5.  The cell biology of multiple drug resistance.

Authors:  W T Beck
Journal:  Biochem Pharmacol       Date:  1987-09-15       Impact factor: 5.858

6.  Adriamycin resistance in HL60 cells and accompanying modification of a surface membrane protein contained in drug-sensitive cells.

Authors:  W Marsh; M S Center
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

7.  Degradation of human anaphylatoxin C3a by rat peritoneal mast cells: a role for the secretory granule enzyme chymase and heparin proteoglycan.

Authors:  J E Gervasoni; D H Conrad; T E Hugli; L B Schwartz; S Ruddy
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

8.  Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance.

Authors:  A A Hindenburg; M A Baker; E Gleyzer; V J Stewart; N Case; R N Taub
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

9.  Surface membrane glycoproteins of wild-type and differentiation-inducer-resistant HL-60 cells.

Authors:  R L Felsted; S K Gupta; C J Glover; R E Gallagher
Journal:  Blood       Date:  1985-09       Impact factor: 22.113

10.  Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.

Authors:  C E Cass; A Janowska-Wieczorek; M A Lynch; H Sheinin; A A Hindenburg; W T Beck
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

View more
  2 in total

Review 1.  Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.

Authors:  M S Center
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

2.  Tunicamycin depresses P-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in L1210 cells.

Authors:  Mário Sereš; Dana Cholujová; Tatiana Bubenčíkova; Albert Breier; Zdenka Sulová
Journal:  Int J Mol Sci       Date:  2011-11-10       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.